Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

Launched by DR. MD. ALIMUR REZA · Jul 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well a medication called Tirzepatide works to help adults with obesity lose weight, compared to following a structured lifestyle program that includes changes in diet and exercise. The study will include adults who have a body weight that is considered overweight or obese (with a body mass index, or BMI, of 25 or higher) and who have not used similar weight-loss medications before. Some participants may have Type 2 Diabetes, but others may not.

If you join the study, you will either receive a once-weekly injection of Tirzepatide or participate in a lifestyle program focused on healthy eating and physical activity. The researchers want to see if Tirzepatide is more effective and safe for weight loss than lifestyle changes alone. To be eligible, participants need to be adults with stable weight in recent months and not have serious medical conditions like certain cancers, pancreatitis, or uncontrolled hormonal problems. Pregnant or breastfeeding women and those planning pregnancy are not eligible. This study is being conducted in Bangladesh and is not yet open for enrolling participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients of both sexes, aged ≥18 years.
• • Body mass index (BMI) ≥25 kg/m².
• • Naïve to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
• • Self-reported stable body weight (change ≤5 kg) over the past 3 months.
• Exclusion Criteria:
• • Diagnosis of diabetes other than Type 2 Diabetes Mellitus.
• • History of chronic or acute pancreatitis.
• • Presence of acute medical conditions, including acute hepatitis, myocardial infarction, stroke, heart failure, febrile illness, or acute diarrheal disease.
• • Evidence of significant, uncontrolled endocrine disorders (e.g., Cushing's syndrome, thyroid disorders, adrenal insufficiency, congenital adrenal hyperplasia).
• • History or presence of malignancy.
• • Active gallbladder disease.
• • Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential, not using adequate contraceptive methods.
• • Prior or planned surgical treatment for obesity.
• • Use of weight-loss products (including prescription medications, over-the-counter drugs, or herbal preparations) within 3 months prior to screening.